HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// Ganji Purnachandra Nagaraju 1 , Olatunji B. Alese 1 , Jerome Landry 2 , Roberto Diaz 3 and Bassel F. El-Rayes 1 1 Department of Hematology and Medical Oncology, Atlanta, USA 2 Department of Radiation Oncology, Emory University, Atlanta, GA 3 Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA Correspondence: Bassel F. El-Rayes, email: // Keywords : Colon cancer, ganetespib, Hsp90, cell cycle progression and chemotherapy Received : August 05, 2014 Accepted : September 15, 2014 Published : September 16, 2014 Abstract Cell cycle progression and DNA synthesis are essential steps in cancer cell growth. Thymidylate synthase (TS) is a therapeutic target for 5FU. We tested the hypothesis that HSP90 transcriptional and functional inhibition can inhibit cell cycle progression, downregulate TS levels and sensitize colorectal cancer (CRC) cell lines to the effects of 5FU. Treatment with ganetespib (50nM) for 24 hours inhibited cyclin D1 and pRb at the transcriptional and translational levels and induced p21, leading to G0/G1 cell cycle arrest in both CRC cell lines (HCT-116 and HT-29). This was associated with downregulation of E2F1 and its target gene TS. In addition, ganetespib inhibited PI3K/Akt and ERK signalling pathways. Similar effects were observed with HSP90 knockdown in both cell lines. Ganetespib sensitized CRC cell lines to the effects of oxaliplatin and 5FU. Similar effects were also observed in tumors from animals treated with ganetespib, oxaliplatin and 5FU. In this study, we present in vitro and animal data supporting that the targeting of HSP90 decreases CRC cell survival and proliferation. Ganetespib sensitizes CRC cell lines to the effects of 5FU-based chemotherapy. Combining HSP90 inhibitors with chemotherapy is a rational approach for future drug development in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 3×
“For example, the EGFR is known to be overexpressed and activated in CRC tumors and cells [27], and its inhibition results in restoration of sensitivity to chemotherapeutic agents [6].”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×
“Constitutive activating mutations in the Ras or Raf genes occur in approximately 45 and 10% of CRC, respectively [8, 9].”
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436 · cited 1×
“These mutations have been associated with poor overall survival as well as resistance to chemotherapy [31], [32].”
Cited by
Sethy, C., & Kundu, C. N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111285 · Cited by 539
Sveen, A., Bruun, J., Eide, P. W., Eilertsen, I. A., Ramirez, L., Murumägi, A., Arjama, M., Danielsen, S. A., Kryeziu, K., Elez, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1234 · Cited by 256
“HSP90 is a molecular chaperone that maintains the 3 homeostasis of many different client proteins and consequently, HSP90 inhibition may block 4 multiple oncogenic signaling pathways simultaneously (39, 44).”
BackgroundResultLi, Q., Wei, L., Lin, S., Chen, Y., Lin, J., & Peng, J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10296 · Cited by 79
Metadata
- Authors
- Nagaraju, G. P., Alese, O. B., Landry, J., Diaz, R., & El-Rayes, B. F.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-09-16
- Volume
- 5
- Issue
- 20
- Pages
- 9980-9991
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1808605164
- Cited by
- 69
- References
- 6
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. https://app.cochat.ai/papers/10.18632/oncotarget.2484
- The paper
- Nagaraju, G. P., Alese, O. B., Landry, J., Diaz, R., & El-Rayes, B. F. (2014). HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. Oncotarget. https://doi.org/10.18632/oncotarget.2484
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.